Bessemer Group
RPRX icon

Bessemer Group’s Royalty Pharma RPRX Stock Holding History

Bessemer Group’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$53K Buy
1,094
+282
+35% +$12.4K ﹤0.01% 1660
2025
Q4 		$32K Buy
812
+461
+131% +$17.6K ﹤0.01% 1757
2025
Q3 		$13K Buy
+351
New +$12.7K ﹤0.01% 1863
2024
Q4 		– Sell
-241
Closed -$7K – 2655
2024
Q3 		$7K Buy
+241
New +$6.67K ﹤0.01% 1807
2023
Q4 		– Sell
-491
Closed -$13K – 2263
2023
Q3 		$13K Buy
+491
New +$14.6K ﹤0.01% 1536
2022
Q2 		– Sell
-170
Closed -$7K – 2007
2022
Q1 		$7K Hold
170
– – ﹤0.01% 1454
2021
Q4 		$7K Sell
170
-869
-84% -$33.8K ﹤0.01% 1506
2021
Q3 		$38K Buy
1,039
+869
+511% +$33.8K ﹤0.01% 1111
2021
Q2 		$7K Hold
170
– – ﹤0.01% 1396
2021
Q1 		$7K Buy
+170
New +$8.06K ﹤0.01% 1363

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Bessemer Group's RPRX Position: Q1 2026 in Review

Bessemer Group increased its Royalty Pharma (RPRX) stake by 35% in Q1 2026, buying an estimated $12.4K and bringing the position to 1,094 shares worth $53K. The position accounts for ﹤0.01% of the portfolio, ranked #1660.

Bessemer Group first reported a position in RPRX in Q1 2021 and has held it in 10 quarters since. 590 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

  • Bessemer Group held 1,094 shares of Royalty Pharma worth $53K as of Q1 2026.
  • Bessemer Group bought 282 Royalty Pharma shares in Q1 2026, an estimated $12.4K.
  • Royalty Pharma made up ﹤0.01% of Bessemer Group's portfolio in Q1 2026, its #1660 holding.
  • Bessemer Group first reported a position in Royalty Pharma in Q1 2021 and has held it in 10 quarters since.
  • 590 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Bessemer Group's 13F filing for Q1 2026, filed 6 May 2026.